A real-world study Anlotinib hydrochloride capsules combined with immune checkpoint inhibitors in patients with advanced non-small cell lung cancer

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2100049975

Enrollment

Unknown

Registered

2021-08-15

Start date

2021-08-15

Completion date

Unknown

Last updated

2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lung cancer

Interventions

Case series:No

Eligibility

Sex/Gender

Male

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years old (calculated on the day of signing informed consent); 2. ECOG PS: 0-2; 3. Histopathologically confirmed non-small cell lung cancer with at least one measurable lesion (according to RECIST 1.1); 4. Has not received systemic treatment before, progressed or did not progress after first-line standard treatment; 5. The patients voluntarily joined the project and signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Small cell lung cancer or tumors with other pathological types; 2. Patients with contraindications to Anlotinib and immunotherapy; 3. Previously received anlotinib hydrochloride for anti-tumor therapy; 4. Patients deemed unsuitable for inclusion by the investigator.

Design outcomes

Primary

Measure	Time frame
effectiveness and safety;	—

Countries

China

Contacts

Public ContactWang Qiming

Henan Cancer Hospital

qimingwang1006@126.com+86 13783590691

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026